Facts and figures
ICON is a global provider of outsourced development services
ICON has approximately 41,100 employees in 111 locations in 53 countries as at December 31, 2022. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
ICON services videoFacts about ICON
About ICON
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
Company history
Organic growth bolstered through a number of strategic acquisitions which have broadened our service portfolio and have added scale to existing services.
Leadership team
ICON has assembled a leadership team with extensive industry experience.
Press releases
ICON's press releases.
Financial figures
- Full year revenue in 2022 of $7,741.4 million, representing an increase of 41.2% on full year 2021 revenue or 45.4% on a constant currency basis.
- Q4 2022 revenue of $1,962 million, representing an increase of 4.3% on Q4 2021 adjusted revenue and 7.6% on a constant currency organic basis.
- Full year 2023 revenue guidance reaffirmed in the range of $7,940 - $8,340 million, representing a year over year increase of 2.6% to 7.7%.
- Full year 2023 adjusted earnings per share guidance in the range of $12.40 - $13.05, representing a year over year increase of 5.5% to 11.1%.
Q4 and full year 2022 financial results